NCT03866187: Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection |
|
|
| Active, not recruiting | 1/2 | 148 | Europe, RoW | ChAd155-hIi-HBV low dose formulation, ChAd155-hIi-HBV high dose formulation, HBc-HBs/AS01B-4 low dose formulation, HBc-HBs/AS01B-4 high dose formulation, MVA-HBV low dose formulation, MVA-HBV high dose formulation, Placebo | GlaxoSmithKline | Hepatitis B, Chronic | 10/25 | 10/25 | | |
